Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease

Doris C. V. Thu,1,2,3 Dorothy E. Oorschot,4 Lynette J. Tippett,2,5 Alissa L. Nana,1,2 Virginia M. Hogg,2,5 Beth J. Synek,6 Ruth Luthi-Carter,3 Henry J. Waldvogel1,2 and Richard L. M. Faull1,2

1 Department of Anatomy with Radiology, University of Auckland, Private Bag 92019, Auckland, New Zealand
2 Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, New Zealand
3 Brain Mind Institute, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
4 Department of Anatomy and Structural Biology, Otago School of Medical Sciences, University of Otago, New Zealand
5 Department of Psychology, University of Auckland, Private Bag 92019, Auckland, New Zealand
6 Department of Forensic Pathology, Auckland City Hospital, Auckland, New Zealand

Correspondence to: Professor Richard L. M. Faull,
Centre for Brain Research,
Faculty of Medical and Health Sciences,
University of Auckland, Private Bag 92019,
Auckland, New Zealand
E-mail: rlm.faull@auckland.ac.nz

Huntington’s disease is an autosomal dominant inherited neurodegenerative disease with motor symptoms that are variably co-expressed with mood and cognitive symptoms, and in which variable neuronal degeneration is also observed in the basal ganglia and the cerebral cortex. We have recently shown that the variable symptomatology in Huntington’s disease correlates with the variable compartmental pattern of GABA_A receptor and cell loss in the striatum. To determine whether the phenotypic variability in Huntington’s disease is also related to variable neuronal degeneration in the cerebral cortex, we undertook a double-blind study using unbiased stereological cell counting methods to determine the pattern of cell loss in the primary motor and anterior cingulate cortices in the brains of 12 cases of Huntington’s disease and 15 controls, and collected detailed data on the clinical symptomatology of the patients with Huntington’s disease from family members and clinical records. The results showed a significant association between: (i) pronounced motor dysfunction and cell loss in the primary motor cortex; and (ii) major mood symptomatology and cell loss in the anterior cingulate cortex. This association held for both total neuronal loss (neuronal N staining) and pyramidal cell loss (SMI32 staining), and also correlated with marked dystrophic changes in the remaining cortical neurons. There was also an association between cortical cell loss and striatal neuropathological grade, but no significant association with CAG repeat length in the Huntington’s disease gene. These findings suggest that the heterogeneity in clinical symptomatology that characterizes Huntington’s disease is associated with variation in the extent of cell loss in the corresponding functional regions of the cerebral cortex whereby motor dysfunction correlates with primary motor cortex cell loss and mood symptomatology is associated with cell loss in the cingulate cortex.
Introduction

Huntington’s disease is an autosomal dominant neurodegenerative disease caused by a CAG expansion in the HD gene (IT15) on the short arm of chromosome 4 (The Huntington’s Disease Collaborative Research Group, 1993). The disease results in neurodegeneration, principally in the basal ganglia and cerebral cortex of the forebrain (Vonsattel et al., 1997), and is characterized by involuntary choreiform movements, as well as mood, cognitive and behavioural symptoms (Vonsattel et al., 1997; Vonsattel and DiFiglia, 1998). Despite the single gene aetiology of Huntington’s disease there is considerable phenotypic variation between cases in the pattern of symptomatology during the course of the disease. Some patients show mainly motor symptomatology at clinical onset and minimal dysfunction of either mood or cognition; while at the other extreme, others show mainly mood and/or cognitive changes, with minimal movement dysfunction until the late stages of the disease. In addition, others show a variable mixed phenotype of motor, mood and cognitive symptoms throughout the course of the disease (Brantd and Butters, 1986; Folstein, 1989; Myers et al., 1991; Claes et al., 1995; Zappacosta et al., 1996; Thompson et al., 2002). Although the number of CAG repeats in the Huntington’s disease gene is negatively correlated with the age of symptom onset (Wexler et al., 2004), there is no clear correlation between the variable symptom profile and CAG repeat number. Indeed, this lack of correlation between clinical phenotype and Huntington’s disease genotype has been clearly demonstrated for monozygotic twins, who showed marked differences in symptom profile despite the inheritance of identical Huntington’s disease genes (Georgiou et al., 1999; Gomez-Esteban et al., 2007).

The major neuronal degeneration in Huntington’s disease occurs in the striatum of the basal ganglia and in the neocortex (Vonsattel et al., 1997). Although Huntington’s disease is characterized by an extensive degeneration of the GABAergic output neurons of the striatum (Reiner et al., 1988; Vonsattel and DiFiglia, 1998; Deng et al., 2004), there is considerable variation between Huntington’s disease cases in the pattern of neurodegeneration between the two major compartments of the striatum—the striosome and matrix (Tippett et al., 2007). Some cases show selective loss of striatal neurons and neurochemical markers in the striosomes (Morton et al., 1993; Hedreen and Folstein, 1995; Augood et al., 1996), while others show selective changes in the matrix (Olsen et al., 1986; Ferrante et al., 1987; Seto-Oshima et al., 1988; Faull et al., 1993), and yet other cases show dual compartmental degeneration (Tippett et al., 2007). Since the differential pattern of connectivity of the striosome and matrix compartments in the mammalian brain suggest that the striosomes may play a role in limbic (e.g. mood) related functions, and the matrix compartment may contribute to motor functions, we recently investigated whether the differential compartmental pattern of striatal degeneration correlated with the variable symptomatology in Huntington’s disease cases. In our study of 35 Huntington’s disease cases (Tippett et al., 2007), we showed a significant association between pronounced mood dysfunction and GABA_A receptor and cell loss in the striosomes, suggesting that part of the variation in clinical symptomatology in Huntington’s disease correlates with the variable pattern of compartmental neurodegeneration in the striatum.

In the present study, we have now extended our findings to determine whether the pattern of neurodegeneration in the cerebral cortex, the other major forebrain region known to be affected in Huntington’s disease, also shows an association with symptom profile. Previous quantitative cell studies have established that widespread regions of the cerebral cortex are affected in Huntington’s disease (Cudkowicz and Kowall, 1990; Hedreen et al., 1991; Heinsen et al., 1994; Macdonald et al., 1997; Macdonald and Halliday, 2002; Selemion et al., 2004). Major losses of pyramidal projection neurons have been documented for cases of Huntington’s disease in various regions of the cerebral cortex including the motor cortex (Macdonald and Halliday, 2002), superior frontal cortex, cingulate gyrus (Cudkowicz and Kowall, 1990) and the angular gyrus of the parietal lobe (Macdonald et al., 1997). These findings of cortical degeneration have been more recently extended in studies using high resolution in vivo magnetic resonance imaging and automated surface reconstruction to measure cortical thickness (Rosas et al., 2002, 2003, 2004, 2005). These in vivo studies in over 30 individuals with Huntington’s disease have elegantly shown a heterogeneous pattern of region-specific thinning of the cerebral cortex in Huntington’s disease with some of the most marked changes being in the sensorimotor cortex and areas of the visual cortex (Rosas et al., 2002, 2008). Distinct motor phenotypes were shown to be associated with discrete patterns of cortical thinning, whereas caudate volumes failed to discriminate the two clinical phenotypes. Rosas et al. (2008) concluded that cortical changes begin early in Huntington’s disease, are regionally heterogeneous and that topologically selective changes in the cerebral cortex might explain much of the clinical heterogeneity found in Huntington’s disease.

In the present study, we first tested the hypothesis that there is a loss of neurons in the primary motor cortex and the anterior cingulate cortex in 12 Huntington’s disease brains compared to 15 control brains for our specific cohort of brains from the Neurological Foundation of New Zealand Human Brain Bank. We then tested the hypothesis that there is heterogeneity in cortical cell loss in Huntington’s disease and that this heterogeneity correlates with symptomatology in a double-blind study of the
12 Huntington’s disease cases. We used unbiased stereological cell counting methods to determine the pattern of total and pyramidal cell loss found post-mortem in the primary motor cortex and the anterior cingulate cortex. These are two functionally diverse regions of the cerebral cortex: the primary motor cortex is known to be involved in the control of motor functions, whilst the anterior cingulate cortex is involved in emotional regulation and mood disturbances (Ebert and Ebmeier, 1996; Davidson et al., 2002; Harrison, 2002; Alexopoulos et al., 2008; Konarski et al., 2008). We then compared the pattern of cortical cell loss in the Huntington’s disease cases with the pattern of motor and mood symptoms present during the disease for each case, as determined by retrospective analysis of clinical symptom data collected from patients, family members and clinical records. Our findings show that the heterogeneity in the motor and mood clinical symptomatology in Huntington’s disease correlates with the heterogeneity of cell loss in the corresponding functional regions of the cerebral cortex and suggest that the pattern of cortical pathology contributes to the variability in behavioural symptomatology in Huntington’s disease.

### Materials and methods

All protocols used in this study were approved by the University of Auckland Human Participants Ethics Committee and informed consent was obtained from all families.

### Neuroanatomical studies

Brain tissue from 12 cases of Huntington’s disease (Table 1) and 15 controls (Table 2) was obtained from the Neurological Foundation of New Zealand Human Brain Bank. The cases of Huntington’s disease included six males and six females, aged 35–75 years (average 61 years), with a post-mortem interval prior to perfusion between 3 and 24 h (average 14 h). The control cases included 10 males and five females with no history of neurological disease, aged 46–79 years (average 64 years), with a post-mortem interval between 5 and 21 h (average 12 h).

Brains were perfused as described previously (Waldvogel et al., 2006) through the basilar and internal carotid arteries, first with phosphate buffered saline with 1% sodium nitrite, followed by 15% of formalin in 0.1 M phosphate buffer (pH 7.4) for 1 h. Following

### Table 1  Huntington’s disease cases

<table>
<thead>
<tr>
<th>Case number</th>
<th>Gender</th>
<th>Age at death</th>
<th>CAG repeat length HD gene</th>
<th>Post-mortem delay (hours)</th>
<th>Grade</th>
<th>Symptoms</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>HC 60</td>
<td>Male</td>
<td>64</td>
<td>18/43</td>
<td>23</td>
<td>3</td>
<td>Mixed</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>HC 68</td>
<td>Female</td>
<td>65</td>
<td>17/42</td>
<td>11</td>
<td>1</td>
<td>Motor</td>
<td>Cardiac arrest</td>
</tr>
<tr>
<td>HC 72</td>
<td>Female</td>
<td>63</td>
<td>17/42</td>
<td>24</td>
<td>2</td>
<td>Motor</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>HC 73</td>
<td>Male</td>
<td>47</td>
<td>19/49</td>
<td>4</td>
<td>2</td>
<td>Motor</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>HC 79</td>
<td>Female</td>
<td>56</td>
<td>17/42</td>
<td>4</td>
<td>1</td>
<td>Mixed</td>
<td>Cardio-respiratory failure</td>
</tr>
<tr>
<td>HC 82</td>
<td>Male</td>
<td>74</td>
<td>15/42</td>
<td>16</td>
<td>2</td>
<td>Mood</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>HC 85</td>
<td>Female</td>
<td>61</td>
<td>24/44</td>
<td>19</td>
<td>3</td>
<td>Mood</td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>HC 93</td>
<td>Female</td>
<td>56</td>
<td>20/43</td>
<td>17</td>
<td>3</td>
<td>Mixed</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>HC 95</td>
<td>Female</td>
<td>66</td>
<td>20/39</td>
<td>12</td>
<td>2</td>
<td>Mood</td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>HC 99</td>
<td>Male</td>
<td>68</td>
<td>21/41</td>
<td>13</td>
<td>2</td>
<td>Motor</td>
<td>Broncho-pneumonia</td>
</tr>
<tr>
<td>HC 101</td>
<td>Male</td>
<td>35</td>
<td>17/44</td>
<td>24</td>
<td>1</td>
<td>Mood</td>
<td>Asphyxia</td>
</tr>
<tr>
<td>HC 107</td>
<td>Male</td>
<td>75</td>
<td>19/43</td>
<td>3</td>
<td>3</td>
<td>Mixed</td>
<td>Broncho-pneumonia</td>
</tr>
</tbody>
</table>

### Table 2  Control cases

<table>
<thead>
<tr>
<th>Case number</th>
<th>Gender</th>
<th>Age of death</th>
<th>CAG repeat length</th>
<th>Post-mortem delay (hours)</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>H 108</td>
<td>Male</td>
<td>58</td>
<td>15/17</td>
<td>16</td>
<td>Coronary atherosclerosis</td>
</tr>
<tr>
<td>H 110</td>
<td>Female</td>
<td>83</td>
<td>17/17</td>
<td>14</td>
<td>Ruptured aortic aneurysm</td>
</tr>
<tr>
<td>H 111</td>
<td>Male</td>
<td>46</td>
<td>17/20</td>
<td>10</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>H 112</td>
<td>Male</td>
<td>79</td>
<td>14/15</td>
<td>8</td>
<td>Bleeding stomach ulcer</td>
</tr>
<tr>
<td>H 115</td>
<td>Male</td>
<td>61</td>
<td>17/19</td>
<td>12</td>
<td>Hypertensive heart disease</td>
</tr>
<tr>
<td>H 118</td>
<td>Male</td>
<td>57</td>
<td>15/16</td>
<td>10</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>H 120</td>
<td>Male</td>
<td>62</td>
<td>18/22</td>
<td>11</td>
<td>Ischaemic heart disease</td>
</tr>
<tr>
<td>H 121</td>
<td>Female</td>
<td>64</td>
<td>18/23</td>
<td>5</td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>H 127</td>
<td>Female</td>
<td>59</td>
<td>15/17</td>
<td>21</td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>H 129</td>
<td>Male</td>
<td>48</td>
<td>20/21</td>
<td>12</td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>H 131</td>
<td>Female</td>
<td>73</td>
<td>17/17</td>
<td>13</td>
<td>Ischaemic heart disease</td>
</tr>
<tr>
<td>H 132</td>
<td>Female</td>
<td>63</td>
<td>15/19</td>
<td>12</td>
<td>Ruptured aorta</td>
</tr>
<tr>
<td>H 136</td>
<td>Male</td>
<td>75</td>
<td>N/A</td>
<td>13</td>
<td>Ruptured abdominal aortic aneurysm</td>
</tr>
<tr>
<td>H 139</td>
<td>Male</td>
<td>73</td>
<td>N/A</td>
<td>5.5</td>
<td>Ischaemic heart disease</td>
</tr>
<tr>
<td>H 330</td>
<td>Male</td>
<td>66</td>
<td>15/15</td>
<td>13</td>
<td>Cor pulmonale</td>
</tr>
</tbody>
</table>
perfusion, blocks (0.75–1.5 cm) were taken from the primary motor cortex and the anterior cingulate cortex of the right hemisphere and kept in the same fixative for 24 h. The blocks from the primary motor cortex were carefully selected from just above the mid dorsoventral region of the precentral gyrus, i.e. the portion corresponding topographically to cortical areas of the upper limb (Fig. 1A). The blocks from the cingulate gyrus were taken from the region of the anterior cingulate cortex immediately dorsal to the genu of the corpus callosum (Fig. 1B). The blocks were then cryoprotected in 20% sucrose in 0.1 M phosphate buffer with 0.1% sodium-azide for 2–3 days and in 30% sucrose in 0.1 M phosphate buffer with 0.1% sodium-azide for a further 2–3 days, then stored at –80°C until further processing.

Blocks were also taken from the basal ganglia for pathological examination. The neuropathologic ‘striatal’ grading of the Huntington’s disease cases was undertaken according to the Vonsattel grading criteria (Grades 0–4) (Vonsattel et al., 1985; Vonsattel and DiFiglia, 1998) by a neuropathologist (B.J.S.) with extensive experience in Huntington’s disease neuropathology. On pathological examination, the control cases showed no neuropathological abnormalities.

For immunohistochemistry each cortical block was sectioned at 50 μm on a freezing microtome and the sections were processed free-floating in six-well tissue culture plates. Two random systematic series of sections were sampled from each entire tissue block from the motor cortex and cingulate cortex for each brain. Each series of sections were washed (3 × 15 min) in phosphate buffered saline and 0.2% Triton-X (phosphate buffered saline-triton), incubated for 20 min in 50% methanol and 1% H2O2, washed, and incubated in primary antibody for 3 days on a shaker at 4°C. The primary antibodies used were mouse anti-neuronal N (NeuN; Chemicon, 1:1000) to immunostain the total population of neurons and mouse anti-SMI32 (Sternberger Monoclonals Incorporated, 1:1000), against the non-phosphorylated epitopes in neurofilaments, to immunostain a subpopulation of pyramidal neurons. Sections that were stained with SMI32 underwent antigen retrieval treatment as described previously (Waldvogel et al., 2006). Sections from both series were washed, incubated overnight in biotinylated goat anti-mouse secondary antibody (Sigma, 1:500), washed, incubated for 4 h at room temperature in ExtrAvidin™ (Sigma, 1:1000), washed, then exposed to 0.05% 3,3-diaminobenzidine tetrahydrochloride (Sigma) and 0.01% H2O2 for 15–20 min to produce a brown reaction product. The sections were washed, mounted on gelatine-chrome-alum coated slides, dried, dehydrated through a graded alcohol series to xylene and coverslipped with Hystomount (Hughes and Hughes, UK). Sections processed to determine non-specific staining by following the same immunohistochemical procedures, but with omission of the primary antibody, showed no immunohistochemical labelling. Before the stereological analyses all sections were coded and blinded.

Figure 1  Diagram showing the location of each cortical block (indicated at 1) that was used for stereological analysis (A) in the primary motor cortex and (B) in the anterior cingulate cortex. Each cross-section of a block indicates the specific Brodmann cytoarchitectural region.
Stereology

In this study, a block (0.75–1.5 cm) of tissue in a well defined subregion of either the primary motor cortex (Fig. 1A) or the anterior cingulate cortex (Fig. 1B) was completely serially sectioned for subsequent stereological analyses. The absolute number of neurons within all of the primary motor cortex (i.e. all of Brodmann area 4) and all of the anterior cingulate cortex (Brodmann area 24) could not be measured because of a lack of tissue availability. While this approach is not stereologically optimal (Oorschot, 1994), an assumption was made that analysis of a quarter to a tenth of each of these cortical regions would yield data that were representative of each entire cortical region. For the primary motor cortex, the observed results were compared with previously reported control and Huntington’s disease data on the absolute number of neurons within the entire primary cortex (i.e. all of Brodmann area 4, Macdonald and Halliday, 2002; see Results and Discussion sections). For the cingulate cortex, the observed results were compared with previously reported control and Huntington’s disease data on the number of neurons per length of cerebral cortex for Brodmann area 24 (Cudkowicz and Kowall, 1990).

The total number of neurons (N) within a defined volume of Brodmann area 4 in the primary motor cortex (Fig. 1A), and within a defined volume of Brodmann area 24 in the anterior cingulate cortex (Fig. 1B), was derived from random systematically sampled sections of each cortical block. The total reference volume (Vref) of each block or defined region was multiplied by the number of neurons in a defined subvolume of each central region (Nv). Thus, N = Vref × Nv.

The total reference volume of each region of interest was determined by using Cavalieri’s direct volume estimate (Gundersen, 1987). This was obtained by estimating the cross-sectional area of each region of interest in 10 systematically sampled sections throughout the defined volume of interest and multiplying the sum of the area of the 10 sections by the distance between each sampled section. The cross-sectional area of each section was estimated using a point-counting method. Each sampled section was projected onto a colour monitor at a known magnification and a lattice of regularly arranged points was superimposed on it. The number of points falling on the region of interest was counted (ΣP) and the total volume was determined using the formula: Vref = ΣP × a(p) × t × 10, where a(p) is the real area that each point represents, t is the average thickness of the sections and ‘10’ is the distance between the sampled sections. The real interpoint distance and real a(p) of a lattice used for each cortical region are listed in Table 3.

The numerical density (Nv) within each cortical region was estimated by using the optical dissector method. The sections used for each region were the same set of sections that were used for Cavalieri’s estimate of volume (Vref) above. Each sampled section was viewed using a 100 × oil immersion objective. The microscope was equipped with a microcatcher on the focus control (to measure the z-axis), an automated mechanical stage and a video camera that projected the image onto an adjacent colour monitor. An unbiased sampling frame of known area was drawn on a transparency sheet and superimposed on the monitor. Each section was sampled systematically (e.g. every 10th area) with a random start. For each cortical region, the area of the unbiased sampling frame used and the sampling interval through each section is listed in Table 4. For each area sampled, neurons were counted only if the neuron fell inside the sampling frame, did not touch the exclusion lines and came into focus through a certain distance (i.e. the dissector height, h) in the middle of each section. The dissector height for each cortical region for each staining is listed in Table 4. The number of neurons (Qi) in a dissector volume [V(dis)ion] in the section was obtained. The V(dis) was determined by multiplying the area of the dissector frame [a(frame)], which was corrected for magnification, by the dissector height (h). Thus, ΣV(dis) = ha(frame). Then, the total value of neuronal density (Nv) in the region of interest for an individual was determined from the formula: Nv = ΣQ / ΣV(dis).

### Statistical analysis

The precision of the estimates made on each case could be estimated with data derived from the set of systematically sampled sections of each case (West and Gundersen, 1990). This precision is termed the coefficient of error and was calculated for the total number of points counted over the sectional profiles of the reference volume (ΣP), and the total number of neurons (N). The coefficients of error were calculated using a revised Matheron’s quadratic approximation formula described in Gundersen et al. (1999). The average coefficient of error for each volume, and for the total number estimate, for each control and Huntington’s disease group was calculated using the formula coefficient of error = (1/n Σ CE)1/2, where n is the number of cases (West and Gundersen, 1990; Gundersen et al., 1999).

### Table 3 Real interpoint distance and the real area of each point used for Cavalieri’s estimate of the total volume of each cortical region

<table>
<thead>
<tr>
<th>Region</th>
<th>Real interpoint distance (mm)</th>
<th>Real area of each point (mm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary motor cortex (BA 4)</td>
<td>2.717</td>
<td>7.38</td>
</tr>
<tr>
<td>Anterior cingulate cortex (BA 24)</td>
<td>2.000</td>
<td>4.00</td>
</tr>
</tbody>
</table>

BA = Brodmann area.

### Table 4 Real sampling frame area, sampling interval and dissector height used for the estimate of Nv by the optical dissector method for neurons stained with NeuN and SMI32 in various cortical regions

<table>
<thead>
<tr>
<th>Region</th>
<th>Real sampling frame area (mm²)</th>
<th>Sampling interval</th>
<th>Dissector height (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeuN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary motor cortex (BA 4)</td>
<td>0.002</td>
<td>1/10th</td>
<td>0.006</td>
</tr>
<tr>
<td>Anterior cingulate cortex (BA 24)</td>
<td>0.0017</td>
<td>1/10th</td>
<td>0.008</td>
</tr>
<tr>
<td>SMI32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary motor cortex (BA 4)</td>
<td>0.0037</td>
<td>1/10th</td>
<td>0.006</td>
</tr>
<tr>
<td>Anterior cingulate cortex (BA 24)</td>
<td>0.0037</td>
<td>1/10th</td>
<td>0.008</td>
</tr>
</tbody>
</table>
The average data resulting from the neuronal cell estimates for the entire tissue block (within Brodmann area 4 in the primary motor cortex and within Brodmann area 24 in the anterior cingulate cortex) were analysed between groups using analysis of variance (ANOVA). A statistical package for social scientists (SPSS), version 12 was used for these ANOVA analyses. Comparison of specific interest groups was analysed using Bonferroni’s post hoc test.

The formula for Bonferroni’s post hoc test is:

$$\frac{\mu_1 - \mu_2}{\text{EMS}[[1/n_1] + (1/n_2)]^{1/2}}$$

where $\mu_1$ is the larger and $\mu_2$ is the smaller of the group means, which correspond to the sample size $n_1$ and $n_2$, respectively. The EMS is the error mean square which was derived by: EMS = error of the sum of squares/degrees of freedom for this error.

This value of error mean square was obtained from the SPSS version 12 computer output.

Correlation of neuroanatomy and the number of CAG repeats

For each Huntington’s disease case, the number of CAG repeats in both alleles of the HD gene was determined by polymerase chain reaction amplification of DNA as previously described (Whitefield et al., 1996). The DNA for amplification was isolated either from blood samples or from cerebellar brain tissue from the same Huntington’s disease cases.

Methods to assess clinical symptomatology

Clinical data were collected retrospectively from family members of the 12 individuals who had died with Huntington’s disease and whose families had requested donation of their brain tissue to the Neurological Foundation of New Zealand Human Brain Bank. The clinical data were collected as part of a larger study using a semi-structured interview and a questionnaire, administered by researchers blind to the neuroanatomical analyses of the brains as previously detailed (van Roon-Mom et al., 2006; Tippett et al., 2007).

The interview format was designed to facilitate the collection of accurate information about the age of clinical onset of Huntington’s disease and the patterns of clinical change related to the disease for each Huntington’s disease case. Initial questions were open and broad and subsequent questions became more specific, which enabled interviewees to tell their version of events before being exposed to the prompts and possible constraints of specific questions. The Clinical Huntington’s disease Questionnaire was developed to provide a comprehensive representation of all reported changes observed in Huntington’s disease and an estimate of the severity of impairment in the motor and mood domains of clinical change in the disease, both at clinical onset and near end-stage (see Tippett et al., 2007 for a detailed description). Due to the retrospective aspect of data collection, assessment of cognitive symptoms was not possible. Questions were posed in language that was readily understandable to the lay-person and were administered with the assistance of the researcher who clarified the content of individual items. Any inconsistencies between information given in the semi-structured interview and responses on the questionnaire were investigated at the end of the session.

Total clinical data for each case (i.e. content of the semi-structured interview and responses on the Clinical Huntington’s disease Questionnaire) were then viewed independently by two psychologists experienced with Huntington’s disease who were blind to the anatomical data obtained for the Huntington’s disease cases. They classified each case according to whether motor symptoms were dominant during the course of the disease, mood symptoms were dominant, or both types of symptoms were significant. Definitions used for these classifications were as follows.

Motor: motor symptoms were present with no significant presence of mood symptoms during the disease course.

Mood: mood disturbance was a dominant clinical feature of Huntington’s disease across the disease course of the individual. There was, however, almost always some degree of motor symptomatology as well, but these symptoms were either very mild, or, only emerged in the very late stages of the disease.

Mixed motor–mood: significant levels of both symptom-types were present during a large part of the disease.

The classifications of the two psychologists were concordant for 90% of cases in the larger study. For any case where there was a difference, the case materials were reviewed by both psychologists until a consensus was reached.

Results

Overall cell loss in the motor and cingulate cortices in Huntington’s disease

In order to investigate the overall cell loss in the primary motor cortex and anterior cingulate cortex in Huntington’s disease, the average total number of cells in a tissue block from each cortical region was measured using unbiased stereological counting techniques in 12 cases of Huntington’s disease and in 15 controls, matched for sex, age and post-mortem delay. There was a significant overall total neuronal cell loss in both Brodmann area 4 of the primary motor cortex and Brodmann area 24 of the anterior cingulate cortex in Huntington’s disease compared to controls (Fig. 2A). In the primary motor cortex (Fig. 2A), there was an average cell loss of 24% ($P<0.002$, single-factor ANOVA test) in the Huntington’s disease cases whereas in the anterior cingulate cortex (Fig. 2A) there was a more pronounced cell loss averaging 36% ($P<0.0005$). The subpopulation of SMI32-positive pyramidal neurons showed a similar pattern of cell reduction in both the primary motor cortex and the anterior cingulate cortex in Huntington’s disease (Fig. 2B) compared to the control cases. On average, there was a significant pyramidal cell reduction of 27% ($P<0.03$) in the primary motor cortex (Fig. 2B) and a reduction of 34% ($P<0.003$) in the anterior cingulate cortex in Huntington’s disease (Fig. 2B). These results are consistent with the findings from an analysis of the absolute number of neurons in the entire primary motor cortex in Huntington’s disease versus control cases (Macdonald and Halliday, 2002). These results are also consistent with the findings from an analysis of the number of SMI32-positive neurons per length of cerebral cortex in the anterior cingulate cortex for Huntington’s disease versus control cases (Cudkowicz and Kowall, 1990). Since there is a reduction in grey
matter volume of the frontal cortex in Huntington’s disease rather than an increased volume due to gliosis (e.g. Halliday et al., 1998), a reduced number of neurons in a subvolume, or per length of cerebral cortex, compared to control cases is likely to be a real biological decrease.

For all stereological analyses for the control and Huntington’s disease cases, the average coefficient of error for the reference volume [i.e. CE(ΣP)] was less than 0.08 and the average coefficient of error for the total number of neurons [i.e. CE(N)] was mostly less than 0.10 and always less than 0.13. This indicates that the estimates of reference volume and total neuronal number were generally reliable (i.e. CE < 0.10). For all analyses, the observed mean variance of the individual total number estimates (i.e. CE²) was less than half of the observed mean variance of the group (i.e. the coefficient of variation, CV²). This indicates that the variability is due to a true difference between cases in the total neuronal number rather than a lack of precision in the stereological counting methods employed (West and Gundersen, 1990).

Variation in the cortical cell loss between Huntington’s disease cases

There was considerable variation between the 12 individual Huntington’s disease cases in the percentage of total neuronal and pyramidal cells lost in both the primary motor cortex and anterior cingulate cortex. As detailed in Fig. 3A, in the motor cortex the total neuronal loss varied from around 50% in four cases (HC60, HC72, HC73, HC93) to 6–28% loss in seven cases (HC68, HC79, HC85, HC99, HC101, HC107), with one case (HC82) showing no significant cell loss. Similarly, in the cingulate cortex, where the cell loss was generally more extensive, the percentage cell loss varied from around 65% in two cases (HC95, HC101), 42–49% in five cases (HC79, HC82, HC85, HC93, HC107), 18–31% in 3 cases (HC60, HC72, HC99), with no significant cell loss in two cases (HC68, HC73; Fig. 3A). Similar trends were also observed in the pattern of pyramidal cell (SMI32) loss; comparison between Huntington’s disease cases showed that the pyramidal cell loss varied in the motor cortex from 59% to no
cell loss, and in the cingulate cortex from 61% to no cell loss (Fig. 3B).

Most interestingly, the total cell loss and pyramidal cell loss in the motor cortex did not always follow the pattern of cell loss in the cingulate cortex (Fig. 3A and B). That is, some cases which showed major cell loss in the motor cortex showed minimal cell loss in the cingulate cortex (e.g. HC73); other cases showed the reverse trend (e.g. HC82) and some showed similar patterns of loss in both cortical regions (e.g. HC93).

Relation between clinical symptoms and differential cell loss in the cerebral cortex

We next investigated whether the variation in the pattern of cell loss in the motor cortex and cingulate cortex was related to the variation in symptomatology. We found marked heterogeneity in the symptoms expressed by the Huntington’s disease patients during the course of the disease. Using the criteria described in the methods, of the 12 Huntington’s disease cases in this study (Table 1), four cases were classified as motor cases (HC68, HC72, HC73, HC99), four were classified as mood cases (HC82, HC85, HC95, HC101) and four were classified as mixed cases, with significant levels of both symptom-types present during a large part of the disease course (HC60, HC79, HC93, HC107). To test whether the differential cortical cell loss between the motor and cingulate cortices was related to the different symptom subtypes exhibited by the different cases, the blinding of the clinical and anatomical assessments was broken, and we compared the average total cell loss and pyramidal cell loss of the cases in each of the three phenotypic groups (motor, mood and mixed motor–mood symptom groups, Fig. 4).

Comparison of the total cell loss in the primary motor cortex and anterior cingulate cortex, in the groups comprising motor or mood cases, showed a clear association between cell loss and symptom phenotype (Fig. 4). In the group of Huntington’s disease cases who experienced mainly motor symptoms, major cortical cell loss was found in the motor cortex [average cell loss of 28% (P < 0.02, Bonferroni’s post hoc test)] with no significant cell loss.
in the cingulate cortex (Fig. 4A). In contrast, in the Huntington’s disease group where mood was the major phenotype of the cases, an extensive cell loss averaging 54% \( (P < 0.0002) \) was found in the cingulate cortex with no significant cell loss in the motor cortex (Fig. 4A). In agreement with this general pattern, the group showing a mixed motor–mood symptomatology showed an extensive cell loss in both the motor cortex (36%, \( P < 0.002 \)) and the cingulate cortex [42% \( (P < 0.001) \), Fig. 4A].

Furthermore, the pattern of cell loss of SMI32-positive pyramidal cells in the motor and cingulate cortices in the mainly motor and mood phenotypic groups (Fig. 4B) closely follows the pattern seen in the total neuronal loss (Fig. 4A); there was a significant major loss of pyramidal cells in the motor symptom group in the motor cortex (45%, \( P < 0.05 \)) with no significant loss in the cingulate cortex (Fig. 4B). The reverse profile applied in the mood subgroup which showed a major pyramidal cell loss in the cingulate cortex (40%, \( P < 0.05 \)) with no significant cell loss in the primary motor cortex (Fig. 4B). Similar to the pattern of total neuronal cell loss, the group of cases showing a mixed motor–mood phenotype collectively showed a significant pyramidal cell loss in both the primary motor cortex (33%, \( P < 0.05 \)) and anterior cingulate cortex [47%, \( (P < 0.05) \), Fig. 4B].

Examination of the cell morphology at high magnification at five representative levels of each cortical block showed the presence of major morphological cell changes in the remaining neurons of the affected cortical regions (Figs 4–6). In all of the cases in the motor and mixed motor–mood phenotype groups, which both showed marked total and pyramidal cell losses in the primary motor cortex, many of the surviving cortical neurons showed marked dystrophic changes suggestive of ongoing pathology (Fig. 5). This was most clearly seen in the surviving pyramidal neurons in layers III and V stained with NeuN and SMI32 which showed marked shrinkage of the cell bodies and extensive loss of dendritic staining (both apical and basal dendrites) (Fig. 5B, C, F and G). In contrast, no obvious change in the neuronal morphology was apparent in the surviving neurons (Fig. 5D and H) in cases with dominant mood symptomatology in which there was no significant cell loss in the motor cortex (Fig. 4). Similar clear-cut morphological changes were also seen in the anterior cingulate cortex of cases with mood symptoms. In all of the mood and mixed mood/motor cases where the

---

**Figure 4** Graph showing (A) the total number of NeuN-positive neurons and (B) SMI32-positive pyramidal neurons (expressed as a percentage of the control) in the primary motor cortex and the anterior cingulate cortex of the three different symptom profile groups of Huntington’s disease cases (HD; motor, mixed and mood). Asterisks indicate statistically significant differences from the control \( (P < 0.05) \) using the Bonferroni post hoc test. Note that the cell loss in the primary motor cortex shows an opposite trend to the anterior cingulate cortex across the three Huntington’s disease symptom groups.
cingulate cortex showed major and selective cell loss (Fig. 4), many of the surviving neurons also showed dystrophic changes (Fig. 6C, D, G and H) similar to those seen in the motor cortex of the motor phenotype cases. In contrast, in the cases of mainly motor symptomatology where there was no significant cell loss in the cingulate cortex, no or minimal change in the morphology of the neurons was shown in the remaining neurons (Fig. 6B and F).

**Relation between the pattern of cell loss in the cerebral cortex and striatal neuropathological grades**

In this study, the 12 Huntington’s disease cases exhibited a range of striatal neuropathological grades as determined by the Vonsattel criteria (Table 1). In order to investigate if there was any relationship between the pathology of the cerebral cortex and the overall pathology of the striatum, we investigated whether there was any relation between the extent of cortical cell loss and the striatal Vonsattel neuropathological grades (Fig. 7).

Analyses of total neuronal cell loss in the motor and cingulate cortices (compared to the control brains) revealed a variable neuronal cell loss in both cortical regions in the different striatal neuropathological grades of the Huntington’s disease cases (Fig. 7A). In general terms, the pattern of average cell loss in the primary motor cortex appeared to parallel the overall increasing striatal neuropathological grades (Fig. 7A). There was no significant cell loss in the motor cortex in the Grades 0–1 group, but there was significant neuronal loss in the motor cortex in the higher neuropathological grades, which showed an increasing trend from Grade 2 (22%, $P < 0.02$) to Grade 3 (35%, $P < 0.002$). By contrast, neuronal loss in the anterior cingulate cortex showed a different pattern with a less apparent correlation to neuropathological grade (Fig. 7A). There was a dramatic and significant cell loss in the cingulate cortex across all Huntington’s disease grades compared to the control with average cell losses of 35% ($P < 0.05$) in Grades 0–1, 31% in Grade 2 ($P < 0.02$) and 42% in Grade 3 ($P < 0.002$) (Fig. 7A).

As shown in Fig. 7B, there was a variable cell loss of SMI32-positive pyramidal neurons in the primary motor cortex and the anterior cingulate cortex in Huntington’s disease across the various striatal neuropathological grades. For the motor cortex, there was a significant cell loss only at Grade 3, 34% ($P < 0.05$) (Fig. 7B). In contrast, the cingulate cortex showed a pattern of pyramidal cell loss which corresponded with the striatal grades.
neuropathological grades, with significant losses evident at the higher neuropathological grades, 36% \((P < 0.05)\) in Grade 2 and 45% \((P < 0.002)\) in Grade 3 (Fig. 7B).

**Comparison of the cell loss in the cerebral cortex with the number of CAG repeats in the HD gene**

We next investigated whether the total cell loss and pyramidal cell loss in the primary motor and anterior cingulate cortices correlated with the CAG repeat lengths in the HD gene. As shown in Fig. 8A and B, there were no significant correlations between the CAG repeat number and total cell loss in either primary motor cortex \((r^2 = 0.1948, P = 0.1509)\) or anterior cingulate cortex \((r^2 = 0.1858, P = 0.1618, \text{Fig. 8B})\), although there appeared to be a trend towards increasing cell loss with increasing CAG repeats in both cortical areas. The correlations between the number of CAG repeats and the loss of SMI32-positive pyramidal cells were also not significant in either the primary motor cortex \((r^2 = 0.1101, P = 0.3188, \text{Fig. 9A})\) or the anterior cingulate cortex \((r^2 = 0.3215, P = 0.0689, \text{Fig. 9B})\).

**Discussion**

Our results suggest that in Huntington’s disease, cell loss in two functionally diverse regions of the cerebral cortex—the primary motor cortex and anterior cingulate cortex—is associated with motor and mood symptomatology, respectively. This detailed stereological study of 12 post-mortem Huntington’s disease brains revealed a major cell loss in these two cortical regions, but interestingly, showed that there is marked variation in the extent of cell loss between individual Huntington’s disease cases. The most striking finding of the study is that the heterogeneous pattern of cell loss in the motor and cingulate cortices in different Huntington’s disease cases corresponds to the variable pattern of motor and mood symptoms presented clinically in these cases. The general implication of our results is that the expanded CAG sequence in the HD gene can produce variable topographical patterns of cortical neuronal degeneration that contribute to specific symptoms. The relationship demonstrated between symptom profiles and cortical degeneration provides a novel perspective on understanding the neural basis of clinical heterogeneity found in Huntington’s disease.

*Figure 6* Photomicrographs illustrating the pyramidal neurons in layer III in Brodmann area 24 of the anterior cingulate cortex of control (A and E) and Huntington’s disease (B–D, F–H) cases (HD) with ‘mainly motor’ (B and F), ‘mixed’ (motor–mood) (C and G) and ‘mainly mood’ (D and H) symptoms. Note that the Huntington’s disease cases all have the same number (42) of CAG repeats on the Huntington’s disease allele of the IT15 gene. (A–D) Pyramidal neurons in layer III of Brodmann area 24 stained with NeuN. (E–H) Pyramidal neurons in layer III of Brodmann area 24 stained with SMI32. Scale bars, A–D and E–H = 30 μm.
Cell loss in the cerebral cortex in Huntington’s disease

Our studies demonstrating marked neuronal loss throughout the motor and cingulate cortices in Huntington’s disease complement and extend the considerable literature showing cortical degeneration throughout many regions of the cortex, such as decreases in post-mortem cortical volume (Mann et al., 1993; Halliday et al., 1998) and neuronal loss and morphological changes (de la Monte et al., 1988; Hedreen et al., 1991; Sotrel et al., 1991, 1993; Heinsen et al., 1994; Macdonald et al., 1997; Macdonald and Halliday, 2002; Rosas et al., 2002, 2008; DiProspero et al., 2004; Selemon et al., 2004). However, of these previous studies only two quantitatively examined cell loss in the motor or cingulate cortices (Cudkowicz and Kowall, 1990; Macdonald and Halliday, 2002).

Our study showed that there is an overall significant loss of 24% of the total neuronal population and 27% loss of SMI32-positive pyramidal cells in the Huntington’s disease primary motor cortex is in general agreement with the previous quantitative study, which showed a major depletion of the total neuronal number (42%) and SMI32-positive pyramidal neurons (41%) in the primary motor cortex of five Grades 2–3 Huntington’s disease cases (Macdonald and Halliday, 2002). Secondly, our studies in the anterior cingulate cortex showed an average 36% total neuronal loss and a 34% loss of SMI32-positive pyramidal cells in Grades 1–3 Huntington’s disease cases; Cudkowicz and Kowall (1990) previously found a significant loss of 25% of SMI32-positive pyramidal neurons in the cingulate cortex in Grade 2–4 Huntington’s disease cases, although Macdonald and Halliday (2002) found no significant change in the total neuronal number in the motor cingulate cortex (i.e. the posterior part of Brodmann area 24) in Grades 2–3 Huntington’s disease cases (Macdonald and Halliday, 2002).

While our findings of an extensive and significant cell loss in the motor and cingulate cortices in Huntington’s disease are in general agreement with the results of prior studies of cortical degeneration in Huntington’s disease, our study demonstrates that there is a surprisingly high variation in the extent of cell loss between the cases that has not been highlighted in previous reports. Comparison between Huntington’s disease cases in our study shows a marked variation in the degree of both the total cell

Figure 7 Graphs showing the total average number of (A) NeuN-positive neurons and (B) SMI32-positive pyramidal neurons (expressed as a percentage of the control) in the primary motor cortex and the anterior cingulate cortex with increasing striatal neuropathological grades (Grades 0–3). Asterisks indicate statistically significant differences from the control ($P < 0.05$) using the Bonferroni post hoc test. HD = Huntington’s disease cases.
and pyramidal cell loss in the primary motor cortex (0–51% loss) and the anterior cingulate cortex (0–65% loss). Most interestingly, we found no association between the pattern of cell loss in the motor cortex and cingulate cortices across the Huntington’s disease cases. In addition, the cell loss in the total neuronal population and in the SMI32-positive pyramidal neurons varied from case to case within each cortical region, although in most cases the pattern of pyramidal cell loss did follow the trend of total cell loss (Fig. 2) confirming previous studies showing that pyramidal cells are the major cell type in the cerebral cortex which are affected in Huntington’s disease (Cudkowicz and Kowall, 1990; Hedreen et al., 1991; Macdonald et al., 1997; Macdonald and Halliday, 2002). This between-case variation in the pattern of cell loss is a novel and characteristic feature of our results showing that there is considerable heterogeneity in the pattern of cortical neuronal degeneration in Huntington’s disease. Since it is well established that there is also variation in symptom profile in Huntington’s disease, then, as discussed below, the next step was to investigate whether this marked variation in cell loss in the motor and cingulate cortices in Huntington’s disease cases may be related to the variation in symptomatology.

### Relationship of cortical cell loss to clinical symptom profile

Huntington’s disease is characterized by a diverse range of symptoms including motor, mood and cognitive disturbances, which vary between patients (Gusella, 1991; Zappacosta et al., 1996; Vonsattel and DiFiglia, 1998). Recently, several different imaging studies in patients with Huntington’s disease have suggested that cortical changes may play a crucial role in the development of clinical symptoms (see Paulsen, 2009 for a review). Studies using functional MRI have identified cortical regions of lower and higher activation in early and premanifest Huntington’s disease during performance on a variety of cognitive tasks (Kim et al., 2004; Wolf et al., 2008), with two studies also demonstrating an association between poor task performance and changes in functional connectivity between cortical regions (Thiruvady et al., 2007; Wolf et al., 2008). These findings concur with results from studies using structural MRI, most significantly those of Rosas et al. (2005, 2008), who measured cortical thinning in pre- and early Huntington’s disease patients using high-resolution surface based analysis of in vivo MRI data. The authors found greater cortical thinning in Huntington’s disease patients with reduced functional

---

**Figure 8** Comparison of total neuronal number (NeuN) in the (A) primary motor cortex and (B) anterior cingulate cortex with the number of CAG repeats in the IT15 gene in the Huntington’s disease cases. There is no significant correlation between the CAG repeats and the total number of neurons.

**Figure 9** Comparison of the number of SMI32-positive pyramidal neurons in the (A) primary motor cortex and (B) anterior cingulate cortex with the number of CAG repeats in the IT15 gene in the Huntington’s disease cases. There is no significant correlation between the CAG repeats and the number of SMI32-positive pyramidal neurons.
scores, and heterogeneous regional patterns of cortical thinning between cases which correlated with heterogeneity in clinical profile (Rosas et al., 2002, 2005, 2008). As highlighted by Paulsen (2009), however, imaging data to date still do not resolve the issue as to whether or not changes in cortical activation or thickness directly reflect death or dysfunction in cells in those regions, or whether they reflect dysfunction from striatal alterations (Paulsen, 2009). Our findings add strong support for the role of cortical pathology in the expression of clinical symptoms in Huntington’s disease by demonstrating a clear association between the pattern of cortical neuronal loss in post-mortem Huntington’s disease brains and the pattern of clinical symptomatology experienced by those individuals during the course of the disease.

In our study, we showed that in the primary motor cortex there was a significant loss of total neurons and SM132-positive pyramidal neurons in Huntington’s disease cases with a dominant motor symptom phenotype (but not in cases with a dominant mood phenotype), which parallels the established role of the primary motor cortex in voluntary movements. In contrast, the anterior cingulate cortex exhibited a significant total cell and pyramidal cell loss in the Huntington’s disease cases with a dominant mood phenotype but not in cases with dominant motor phenotype. The anterior cingulate cortex is one of the major components of the limbic system and may play an important role in both mood and cognitive impairment (Davidson et al., 2002; Georgiou-Karistianis et al., 2007; Thiruvady et al., 2007; Alexopoulos et al., 2008). Our previous study on the basal ganglia has shown a greater mood dysfunction associated with greater damage to the striosome compartment of the striatum (Tippett et al., 2007), which receives input from the limbic related cortical areas including the anterior cingulate cortex (Eblen and Graybiel, 1995). This suggests that the profile of mood symptoms in Huntington’s disease is likely to be associated with degeneration in limbic regions with extensive projections to the striatum. Thus, our results showing a variable pattern of neurodegeneration in the two cortical regions studied provide evidence suggesting a significant association between neuronal degeneration in the human cerebral cortex and the symptom profile in Huntington’s disease.

The correlation of the clinical symptom profiles in Huntington’s disease with the cortical pathology was not only shown by the pattern of cell loss but also in the dystrophic morphology of the surviving neurons in the two cortical regions. In both the motor and cingulate cortices, pyramidal neurons were particularly affected, with major morphological changes evident, including cell shrinkage and loss of stained dendritic processes in the corresponding symptom profile cases—i.e. the most marked dystrophic changes in the motor and cingulate cortices were seen in those cases with the most marked motor and mood symptom profiles. Morphological changes in the pyramidal cells including dendritic remodelling, altered size and number of dendritic spines have been previously observed in Huntington’s disease cortex prior to degeneration (Sapp et al., 1997) and transgenic mouse models of Huntington’s disease (Laforet et al., 2001). The observation of marked neuronal dystrophic changes correlating with symptom profile in our studies provides suggestive evidence for ongoing progressive neuronal dysfunction and physiological stress in the cerebral cortex which may contribute to the variable developing symptom phenotypes seen in Huntington’s disease.

### Relationship of cortical cell loss to striatal degeneration and neuropathological grade

The extensive anatomical connections between the cerebral cortex and the striatum through the topographically organized corticostriate projection make it very difficult to define how dysfunction and degeneration in the cerebral cortex and the striatum, alone or in combination, contribute to symptom profile. Nevertheless, comparison of cortical cell loss in Huntington’s disease cases with striatal neuropathological grade may well shed light on the pathogenesis. In our study, the neuronal cell loss in the primary motor cortex generally increased with increasing striatal neuropathological grades suggesting a close relationship between cortical and striatal degeneration; this is consistent with Macdonald and Halliday (2002) who found major cortical neuronal loss of greater than 40% in Grades 2–3 Huntington’s disease cases. These general findings suggest a linkage of cortical and striatal degeneration. Nevertheless, the finding in our study of significant major cell loss in the cingulate cortex across all striatal neuropathological grades suggests that the degeneration in the cerebral cortex does indeed play a key role in Huntington’s disease pathogenesis.

Generally, in our study the pyramidal cell loss in Huntington’s disease cases correlated closely with the total cell loss, suggesting that in Huntington’s disease mainly projection neurons in layers III, V and VI are affected. This agrees with previous cortical studies (Cudkowicz and Kowall, 1990; Hedreen et al., 1991; Sotrel et al., 1997; Macdonald et al., 1997; Macdonald and Halliday, 2002) showing that the pyramidal cells, which are the major output neurons of the cortex, are the major cortical cell type affected in Huntington’s disease. Death of cortical pyramidal cells in the Huntington’s disease brain may contribute to dysfunction in other cortical and subcortical regions, particularly the striatum. The dysfunctional changes in corticostriatal projections that occur in Huntington’s disease may originate at the level of gene expression. This is supported by our recent microarray analysis of primary motor cortex from 34 Grades 0–2 Huntington’s disease cases (including cases used in the present study), which indicated that 3% of mRNAs (1482) were differentially expressed (Hodges et al., 2006). In addition, this study showed greater abnormalities in mRNA expression in the motor cortex than in prefrontal association cortex, demonstrating a regionally distinct pattern of differential expression that may correspond to the severity of effects (or, alternatively, to a heterogeneity of mechanisms) in different cortical regions in Huntington’s disease. As a prominent example, it is well established that brain-derived neurotrophic factor, a neurotrophin important for striatal neuron survival (Cattaneo et al., 2001; Ferrer et al., 2001; Zuccato et al., 2001), is produced by cortico-striatal pyramidal projection neurons and transported in an anterograde manner to the striatum (Altar et al., 1997) and that in Huntington’s disease, decreases in cortical brain-derived neurotrophic factor gene transcription (Zuccato et al., 2001) and defects in brain-derived neurotrophic factor transport (Gauthier et al., 2007).
2004) may result in reduced brain-derived neurotrophic factor expression to support the striatum leading to striatal neurodegeneration. A recent study of mRNA changes in layer-five projection neurons in the primary motor cortex in Huntington’s disease has also shown a decrease in both mRNA and protein levels of Lin7b, a protein involved in neuronal polarity and synaptic connectivity (Zucker et al., unpublished).

**Relationship of cortical cell loss to CAG repeat length**

We found no significant correlation between CAG repeat numbers and neuronal cell loss in the cortex. This contrasts with findings of a significant relationship between CAG repeat numbers and the extent of neuronal loss in the caudate nucleus and the putamen or gross striatal neuropathological grade (Penney et al., 1997; Vonsattel and DiFiglia, 1998). Although this may be due to the small sample size in the present study, it could also suggest that the neurodegeneration in the cortex (unlike the striatum) is not strongly dependent on CAG repeat length. This is supported by our finding that cases with the same number of CAG repeat length showed a marked variation in the extent of cortical cell loss and symptom profiles. In addition, clinical expression of Huntington’s disease in monozygotic twins can also be markedly different despite the same number of CAG repeats (Georgiou et al., 1999; Gomez-Esteban et al., 2007), suggesting that the effects of the mutant HD gene may be modified by other genetic and environmental factors. Indeed, studies on transgenic animal models of Huntington’s disease show that environmental enrichment has a clear influence on neurochemical degenerative changes in the basal ganglia and on symptom progression (van Dellen et al., 2000; Glass et al., 2004; Spansari et al., 2004). Also, consideration of the correlation of age of onset with CAG repeat size in Huntington’s disease, suggests that 40% of the variability may be accounted for by modifying genes and environmental effects (Wexler et al., 2004). Taken together with our present findings that regional cortical pathologies correlate with specific symptomatic profiles, it is interesting to consider whether gene and environmental modifier effects may also act on regionally variant substrates to play a role in determining Huntington’s disease phenotype characteristics.

**Mechanisms of cortical degeneration**

The exact mechanisms of neuronal cell death in Huntington’s disease are currently unclear but may involve transcriptional dysregulation, excitotoxicity, oxidative stress, changes in neurotransmitters, cortical brain-derived neurotrophic factor production, and breakdown of cellular and vesicular transport mechanisms. Recent transgenic animal studies have implicated dysfunction of the cortex as one of the major indicators of phenotype; this may occur through cortical synaptic dysfunction before cell death (Cepeda et al., 2007; Cummings et al., 2009). Dysfunction of the corticostriatal pathway involves complex and multiple changes that have been documented and which may lead to neurodegeneration of both cortical and striatal neurons; mutant Huntingtin’s effects in cortical neurons cause dysfunction of the corticostriatal pathway and dysregulation of neurotransmitter and brain-derived neurotrophic factor release which probably impairs the functioning of the striatal neurons (Cepeda et al., 2007; Strand et al., 2007). Also, abnormal cortical glutamate receptor functions have been implicated in behavioural and motor impairments in transgenic mice with physiological and morphological cortical changes predicting the onset and severity of behavioural deficits (Laforet et al., 2001; Andre et al., 2006). Furthermore, studies in the conditional mouse model where cortical and/or striatal cells selectively expressed mutant huntingtin, dysfunction of the cortical neurons was essential to the development of significant behavioural and motor deficits (Gu et al., 2007). Other transgenic mouse studies have implicated dysfunction of both the cortical projection and interneurons in the development of Huntington’s disease pathology (Gu et al., 2005; Spansari et al., 2008). All of these animal studies provide accumulating mechanistic evidence that the cortex plays a major role in the initiation and development of the Huntington’s disease phenotype, and that dysfunction in the corticostriate neurons plays a central role in Huntington’s disease forebrain pathology.

Our studies here in the post-mortem Huntington’s disease human brain together with the in vivo findings of Rosas et al. (2008) in patients with Huntington’s disease demonstrate that the heterogeneous pattern of cortical degeneration correlates with phenotype variability and further confirms the determining role of the cerebral cortex in Huntington’s disease aetiology and manifestation.

**Conclusion**

The results of the present study have shown major cell loss in the primary motor and anterior cingulate cortices in Huntington’s disease. Loss in the primary motor cortex increases with Huntington’s disease grade whereas loss in the anterior cingulate cortex was similar across all grades. Most strikingly, when cases were classified into symptom categories, there was a marked cell loss in the primary motor cortex in cases with prominent motor symptoms and a marked cell loss in the anterior cingulate cortex in cases with prominent mood symptoms. These results provide evidence that the heterogeneity and specific nature of clinical symptomatology experienced by patients with Huntington’s disease can be at least partly accounted for by heterogeneous neurodegeneration in particular functional regions of the cerebral cortex. These findings extend and complement recent in vivo MRI findings of Rosas and colleagues (2008) showing that variable patterns of cortical thinning in patients with Huntington’s disease parallels clinical heterogeneity. The mechanisms underlying neuronal loss in the cerebral cortex are still unclear but may be a combination of disrupted microcircuitry, excitotoxicity and neurochemical imbalances. The cortical degeneration-to-symptom relationship we report here suggests that cortical neurodegeneration is a key component in understanding the neural basis of clinical hereogeneity in Huntington’s disease.
Acknowledgements

We express our appreciation to the Huntington’s families in New Zealand and the Huntington’s Disease Associations of New Zealand for their generous and invaluable assistance, and to the Neurological Foundation of New Zealand Human Brain Bank.

Funding

Health Research Council of New Zealand; the Neurological Foundation of New Zealand; Matthew Oswin Memorial Trust.

References


Augood SJ, Faull RLM, Love DR, Emson PC. Reduction in enkaphalin and


Oorschot DE. Are you using neuronal densities, synaptic densities or neurochemical densities as your definitive data? There is a better way to go. Prog Neurobiol 1994; 44: 233–47.


